Physician
United Urgent Care and Wellness Center, INC.
United Urgent Care and Wellness Center, INC. was paid $2.02M by Medicaid between Mar 2019 and Nov 2024, across 125 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 11% of everything it billed.
33Billing provider infoUNITED URGENT CARE AND WELLNESS CENTER, INC.
CARSON, CA 90745
CARSON, CA 90745
33aNPI1275948994assigned 06/23/2014
33bProvider typeDiagnostic Radiology Physician
28Total paid$2.02M
24GClaims150,282
24DCodes billed125
24AFirst – last monthMar 2019 – Nov 2024
Compared with peers
Next to other Diagnostic Radiology Physician providers in California
Rank by total paid#47 of 797
Median peer was paid$6K
This provider vs. median359×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 21 | $184.31 | |
| 2020 | 2,334 | $24K | |
| 2021 | 18,966 | $242K | |
| 2022 | 38,755 | $534K | |
| 2023 | 42,941 | $589K | |
| 2024incomplete | 47,265 | $627K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 6,586 | 5,938 | $231K |
| S9083 | Global fee urgent care centers | 8.9% | 9,068 | 7,524 | $180K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.4% | 5,797 | 5,231 | $130K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.1% | 2,316 | 2,311 | $123K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.9% | 3,399 | 3,352 | $119K |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | 5.8% | 9,100 | 7,547 | $117K |
| 93975 | 5.0% | 961 | 936 | $100K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.4% | 4,357 | 4,208 | $88K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.7% | 3,864 | 3,768 | $75K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.7% | 1,687 | 1,682 | $74K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.0% | 3,709 | 3,632 | $61K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.6% | 934 | 888 | $52K |
113 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.3% | 3,421 | $47K |
| 87428 | 2.0% | 1,304 | $41K | |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 2,788 | $40K |
| 70486 | 1.9% | 621 | $38K | |
| 99401 | 1.8% | 15,216 | $36K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,308 | $33K |
| 99354 | 1.6% | 1,770 | $32K | |
| 93880 | 1.5% | 327 | $30K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.2% | 688 | $25K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 2,060 | $24K |
| 76770 | 1.1% | 694 | $23K | |
| 99423 | <1% | 1,356 | $19K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,828 | $16K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 944 | $15K |
| 99205 | Prolong outpt/office vis | <1% | 228 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,292 | $14K |
| 76377 | <1% | 3,804 | $14K | |
| 36410 | <1% | 2,288 | $13K | |
| 99406 | <1% | 1,376 | $12K | |
| 99058 | <1% | 3,955 | $11K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 321 | $11K |
| 87634 | <1% | 376 | $8K | |
| 99051 | <1% | 2,287 | $8K | |
| 51798 | <1% | 293 | $7K | |
| 70480 | <1% | 84 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,646 | $7K |
| 99402 | <1% | 1,441 | $6K | |
| 87081 | <1% | 2,009 | $6K | |
| 99050 | <1% | 2,289 | $6K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,095 | $6K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 221 | $6K |
| 93000 | <1% | 340 | $5K | |
| 99443 | <1% | 449 | $5K | |
| G0425 | Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth | <1% | 826 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 105 | $4K |
| 99000 | <1% | 1,732 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 299 | $4K |
| 94644 | <1% | 303 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 62 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 257 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 676 | $3K |
| 87070 | <1% | 630 | $2K | |
| 1111F | <1% | 11,476 | $2K | |
| 81003 | <1% | 2,020 | $2K | |
| 75571 | <1% | 45 | $2K | |
| 87338 | <1% | 371 | $2K | |
| 1008F | <1% | 11,329 | $2K | |
| 93970 | <1% | 25 | $2K | |
| 99355 | <1% | 97 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 380 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 287 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 118 | $2K |
| 86308 | <1% | 582 | $2K | |
| 93040 | <1% | 294 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,449 | $1K |
| 97598 | <1% | 56 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 384 | $1K |
| 77089 | <1% | 74 | $1K | |
| 72100 | <1% | 83 | $1K | |
| 97597 | <1% | 61 | $1K | |
| 80061 | Lipid panel | <1% | 181 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 152 | $1K |
| 11047 | <1% | 59 | $1K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 101 | $997.38 |
| 77080 | <1% | 60 | $853.35 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 179 | $831.81 |
| 16020 | <1% | 42 | $692.78 | |
| A7016 | Dome and mouthpiece, used with small volume ultrasonic nebulizer | <1% | 246 | $637.50 |
| 99001 | <1% | 548 | $573.65 | |
| 83690 | <1% | 193 | $549.91 | |
| 99417 | Prolong home eval add 15m | <1% | 122 | $527.49 |
| 77086 | <1% | 59 | $511.66 | |
| 82746 | <1% | 50 | $443.28 | |
| 77081 | <1% | 59 | $435.28 | |
| 72040 | <1% | 26 | $429.69 | |
| 87420 | <1% | 283 | $427.76 | |
| 82607 | <1% | 62 | $411.41 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 28 | $393.04 |
| 84702 | <1% | 56 | $382.79 | |
| 86328 | <1% | 13 | $316.61 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 244 | $301.82 |
| 74022 | <1% | 13 | $292.43 | |
| 84436 | <1% | 107 | $291.42 | |
| 87563 | <1% | 27 | $269.74 | |
| 82728 | <1% | 38 | $240.08 | |
| 73564 | <1% | 13 | $220.48 | |
| 87075 | <1% | 38 | $175.86 | |
| 83550 | <1% | 50 | $171.41 | |
| 73562 | <1% | 13 | $139.36 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $125.17 |
| 86696 | <1% | 14 | $123.30 | |
| 86695 | <1% | 28 | $119.04 | |
| 81001 | <1% | 61 | $118.08 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 283 | $109.12 |
| 83540 | <1% | 37 | $102.48 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 13 | $100.00 |
| 73630 | <1% | 12 | $95.92 | |
| 87205 | <1% | 50 | $92.97 | |
| 87164 | <1% | 14 | $76.20 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12 | $74.71 |
| A4550 | Surgical trays | <1% | 184 | $73.75 |
| 87905 | <1% | 12 | $64.72 | |
| A4554 | Disposable underpads, all sizes | <1% | 149 | $63.42 |
| 84479 | <1% | 24 | $56.50 | |
| 85045 | <1% | 25 | $49.34 | |
| J3490 | Unclassified drugs | <1% | 14 | $44.19 |
| 97602 | <1% | 54 | $35.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 25 | $25.78 |
| 99072 | <1% | 199 | $23.85 | |
| 86592 | <1% | 13 | $19.62 | |
| 99070 | <1% | 29 | $8.75 | |
| 99080 | 0% | 12 | $0.00 | |
| 98968 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMAZAHERI, SHAHRZAD (MANAGER)